Eli Lilly and Novo Nordisk at the Center of Drug Pricing and Brand Protection Battles
Nov/05/2025
The Trump administration is finalizing agreements with weight-loss drugmakers Eli Lilly and Novo Nordisk to offer low-dose GLP-1 drugs such as Wegovy and Zepbound at sharply reduced prices—$149 and $299 per month, respectively—through a new federal platform, TrumpRx. The initiative, which would also expand Medicare and Medicaid coverage for obesity treatments, marks a significant policy shift in U.S. drug pricing. Meanwhile, Eli Lilly has intensified its global brand protection drive, securing WIPO rulings transferring domains such as mounjaro-israel.com and zepboundonline.shop, which had been selling unauthorized pharmaceuticals. Both drugmakers are navigating a booming yet increasingly contested weight-loss market, with Novo Nordisk’s Ozempic and Lilly’s Zepbound generating record revenues as Washington seeks to make such treatments more affordable while reining in spiraling healthcare costs.
